MediPharm Labs (TSX: LABS) recently announced a major milestone by returning to positive net income in the second quarter, marking its first profitable quarter since 2019 alongside a second consecutive period of positive adjusted EBITDA. Propelled by surging international medical cannabis sales in Germany and positive Phase II dementia trial data for its proprietary formulations, the stock has captured renewed investor attention as a developing turnaround play trading on major Canadian exchanges.